| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
Department of Medical Oncology, Dana-Farber Cancer Institute [M. S., Y. B. P., J. L. G., S. C. C., L. A. Q., K. P.]; Department of Medicine, Brigham and Women’s Hospital, and Harvard Medical School, Boston, Massachusetts 02115 [M. S.]; University of Chicago, Pritzker School of Medicine, Chicago, IL 60637 [P. M., R. S.]; and Sugen, San Francisco, California 94080 [S. S., C. L., J. G. C.]
 |
ABSTRACT |
|---|
 Top ABSTRACT INTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
|
INTRODUCTION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Met serves as the high-affinity receptor for HGF. HGF was identified as a growth factor for hepatocytes and as a fibroblast-derived cell motility factor, or scatter factor. HGF is a disulfide-linked heterodimeric molecule produced predominantly by mesenchymal cells and acting in an endocrine or paracrine fashion. Ligation of the Met receptor by HGF has been shown to regulate cell growth and motility, as well as embryological development, wound healing, tissue regeneration, angiogenesis, growth, invasion, and morphogenic differentiation. Therefore, deregulation of these processes by activated forms of Met in human cancer is of special interest. Met mutations have been described in hereditary and sporadic human papillary renal carcinomas and have been reported in ovarian cancer, childhood hepatocellular carcinoma, metastatic head and neck squamous cell carcinomas, and gastric cancer. There is also overexpression of Met in both non-small cell lung cancer and small cell lung cancer cells (for review, see Ref. 16 ).
Because Met and transforming forms of Met are thought to play an important role in oncogenesis of a variety of tumors (16) , we sought to target the Met tyrosine kinase for drug development. c-Met would be an attractive therapeutic target for inhibition in diseases with mutated Met or overexpression of Met, such as small cell lung cancer. However, unlike Gleevec for CML (targeting BCR-ABL) and gastrointestinal stromal tumor (targeting c-Kit), no targeted small molecule inhibitors against c-Met have been developed yet. Nonetheless, Morotti et al. (17) have recently reported inhibitory activities of K252a, a member of a group of natural alkaloids, against the oncogenic properties of c-Met at a concentration 100 nM or less. K252a acts as a kinase inhibitor by competing with the binding of ATP to the catalytic domain and was originally described as a serine/threonine kinase inhibitor, which later was also found to be a potent inhibitor of Trk family members and a partial inhibitor of PDGF receptor. Interestingly, K252a exhibited more potent inhibition for the strongly activating M1268T-Met mutation, than for wild-type Met. However, it remains an open question whether broad-spectrum or highly specific kinase inhibitors would exhibit more effective therapeutic value with reasonable safety profiles.
Using the TPR-MET oncogene with constitutively activated Met tyrosine kinase activity, we developed a cell line model system suitable to identify small molecule drugs as inhibitors of Met kinase activity. We have developed a small molecule drug specifically inhibiting the Met tyrosine kinase in vitro and in cell lines. Inhibition of the Met kinase activity by the novel small molecule drug SU11274 [(3Z)-N-(3-chlorophenyl)-3-({3,5-dimethyl-4-[(4-methylpiperazin-1-yl)carbonyl]-1H-pyrrol-2-yl}methylene)-N-methyl-2-oxo-2,3-dihydro-1H-indole-5-sulfonamide] led to time- and dose-dependent reduced cell growth and did not inhibit BCR-ABL, TEL-JAK2, TEL-PDGFßR, or TEL-ABL tyrosine kinases. SU11274 inhibition of TPR-MET kinase activity induced G1 cell cycle arrest and apoptosis with increased Annexin V staining and caspase 3 activity. Also, SU11274 inhibited phosphorylation of key regulators of the PI3K pathway, including AKT, FKHR, or GSK3ß. Lung cancer cell lines overexpressing c-Met, H69 and H345, also had growth inhibition with SU11274, with biochemical evidence of inhibition of phosphorylated c-Met. The characterization of SU11274 as an effective inhibitor of Met tyrosine kinase activity illustrates the potential of targeting Met in cancers associated with activated forms of the Met receptor tyrosine kinase.
|
MATERIALS AND METHODS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Drugs.
SU11274 (SUGEN, Inc.) and Gleevec (STI-571, imatinib mesylate; Novartis Pharmaceuticals) were dissolved in DMSO and used at the concentrations described.
In Vitro Kinase Assays.
The IC50 (50% inhibitory concentration) values of SU11274 for the inhibition of various kinases was determined as described previously (18)
. Human c-Src was a full-length purified recombinant protein, and Met, FGFR1, EGFR, Flk-1, and Tie-2 were generated as glutathione S-transferase fusion proteins. IC50 measurements of PDGFßR autophosphorylation were determined on immunoprecipitated PDGFßR. The phosphorylation of histone in the presence of 33P-ATP was used for IC50 determination of cyclin-dependent kinase 2 activity. IC50 measurements with all other kinases were made using poly-Glu-Tyr (4:1) as a peptide substrate. The divalent cation in the reaction was 20 mM MgCl2 (Src) or 10 mM MnCl2 (EGFR, Met, FGFR1, Flk-1, Tie2). The linear range (i.e., the time period over which the rate remained equivalent to the initial rate) was determined for each kinase. All kinetic measurements and IC50 determinations were performed within this range. Km values were calculated using the Eadie-Hofstee method, and the final ATP concentrations were within two to three times the Km value.
Transwell Migration Assay.
The lower chamber of a transwell plate (8-µm pore size polycarbonate membrane; Corning Costar Corp., Cambridge, MA) was filled with 600 µl starvation media [0.5% (w/v) BSA in RPMI 1640]. Cells were counted using a Coulter particle counter (Coulter Counter Z2; Beckman Coulter, Fullerton, CA) and resuspended at 2 x 106 cells/ml in starvation media. One hundred microliters of this cell suspension was transferred to the upper chamber. The medium contained either SU11274 (3 µM) or DMSO in the control samples. After 4 h, cells in the lower compartment were resuspended and counted using a Coulter particle counter. The spontaneous transwell migration of cells was expressed as a "migration index" (number of migrating cells treated with SU11274 divided by the number of migrating cells left untreated). The SE was calculated from the migration indices of independently performed experiments. The statistical significance of the data was analyzed using the Student’s t test.
Immunoblotting.
Proteins were extracted from whole cells by lysing them in a Tris buffer (50 mM, pH 8.0) containing NaCl (150 mM), NP40 (1% v/v), deoxycholic acid (0.5% w/v), SDS (0.1% w/v), NaF (1 mM), Na3VO4 (1 mM), and glycerol (10% v/v; Sigma Chemical Co.) supplemented with a protease inhibitor mixture (complete; Roche, Indianapolis, IN). Polyclonal rabbit antibodies against tyrosine phosphorylated Met (Biosource International, Camarillo, CA), PI3K (Upstate Biotechnology, Lake Placid, NY), or tyrosine phosphorylated GSK3ß, FKHR, or AKT (Cell Signaling, Beverly, MA) and mouse monoclonal antibodies against Abl (Oncogene, San Diego, CA) or phospho-tyrosine (Upstate Biotechnology) were used for immunoblotting or immunoprecipitation.
Apoptosis Assays.
The activity of caspase-3 was measured in cell lysates (CaspACE Assay System; Promega), and Annexin V-positive staining was determined by fluorescence-activated cell sorter analysis (Annexin-V-Fluos Staining Kit; Roche Diagnostics), according to the manufacturer’s directions, in cells that were either treated with SU11274 or the solvent DMSO.
Cell Cycle Analysis.
Fixed cells were stained with propidium iodide, and cell cycle parameters were analyzed by fluorescence-activated cell sorter analysis.
|
RESULTS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
, top). SU11274 exhibited activity against Met enzyme in vitro with an average IC50 of 0.02 µM. In addition, SU11274 exhibited greater than 50-fold selectivity for Met enzyme versus a panel of other tyrosine kinases (Table 1)
. For example, at the IC50 of SU11274 for Met inhibition, there was no inhibition of PDGFßR kinase activity and only about 2% inhibition of FGFR-1 kinase activity (Fig. 1
, bottom). The IC50 of SU11274 for PDGFßR inhibition was more than 1000-fold higher, and that for FGFR-1 inhibition about 500 times higher than the IC50 of SU11274 for inhibition of Met. The cellular activity and good selectivity against other kinases suggests that SU11274 should have use as a prototype inhibitor for the investigation of Met biology.
|
|
. Treatment of BaF3.TPR-MET cells with SU11274 was found to inhibit cell growth in a dose-dependent manner with an IC50 <3 µM. In the presence of interleukin 3, the kinase inhibitor also inhibited cell growth at concentrations larger than 1 µM. Inhibition of cell growth at higher concentrations was not a result of general toxicity of the drug, because there was no growth inhibition in BCR-ABL-transformed BaF3 cells (Fig. 2A)
. This difference is likely because of the regulation of a pathway that is required for interleukin 3 signaling by the TPR-MET kinase. SU11274 (1 µM, 18 h) also did not inhibit cell growth of BaF3 cells transformed by other oncogenic tyrosine kinases, including BCR-ABL, TEL-JAK2, TEL-ABL, and TEL-PDGFßR (Fig. 2B)
. To further determine whether the growth inhibitory effect of SU11274 on BaF3.TPR-MET cells accumulates over time, the cell growth was determined over a 3-day culture. In the presence of interleukin 3, SU11274 did not reduce cell growth of TPR-MET-transformed cells or BCR-ABL-transformed cells in a control experiment (Fig. 2C
, top). In contrast, SU11274 completely blocked cell growth in the absence of interleukin 3 in BaF3.TPR-MET (P < 0.0001) but not in BaF3.BCR-ABL (Fig. 2C
, bottom). This suggests that interleukin 3 completely rescues the BaF3.TPR-MET cells from SU11274-dependent growth inhibition. We did not observe a significant growth inhibitory effect of SU11274 at 1 µM in interleukin 3-stimulated parental BaF3 cells in a 3-day culture (data not shown). TPR-MET is, therefore, implicated in the deregulation of pathways normally used by the activated interleukin 3 receptor, similarly to the relation between the Abl inhibitor STI-571 and the BCR-ABL oncoprotein.
|
. Migration of BaF3.TPR-MET cells was inhibited with 1 µM SU11274 (44.8 ± 13.8% inhibition of the cell migration; P < 0.01) and with 5 µM SU11274 (about 80% inhibition of the cell migration; P < 0.0001), compared with DMSO-treated cells. This demonstrates that the TPR-MET kinase activity regulates cell growth and migration of BaF3 cells.
In cellular assays, SU11274 demonstrated inhibition of HGF-dependent phosphorylation of Met as well as HGF-dependent cell proliferation and motility with a mean IC50 of 1–1.5 µM (data not shown). Cytotoxicity was not observed in non-Met-expressing cells at concentrations up to 25 µM. In addition to TPR-MET-dependent cell growth, we also determined the effect of SU11274 on proliferation in the H69 and H345 lung cancer cell lines. H69 and H345 cells express the functional Met receptor but do not require exogenous HGF for cell growth and survival. Cell growth in the presence of HGF (40 ng/ml) was found to be inhibited in a dose-dependent manner (Fig. 2E)
. The IC50 values of SU11274 for the inhibition of cell growth in H69 cells (3.4 µM) and H345 cells (6.5 µM) were comparable with the IC50 in BaF3.TPR-MET cells.
SU11274 Inhibits Tyrosine Phosphorylation of Cellular Proteins in TPR-MET-transformed BaF3 Cells.
To determine the biochemical consequences of Met kinase inhibition by SU11274 in BaF3 cells, changes in tyrosine phosphorylation of cellular proteins were evaluated. In whole cell lysates of BaF3.TPR-MET cells, compared with BaF3.BCR-ABL, tyrosine phosphorylation of a set of unique and overlapping tyrosine phoshorylated proteins were observed, with prominent tyrosine phosphorylation of either oncogenic tyrosine kinase (Fig. 3A
, right). In particular, the Mr 65,000 TPR-MET kinase induced significant tyrosine phosphorylation of a Mr 140,000–145,000 protein band that appeared only weakly tyrosine phosphorylated in BCR-ABL-transformed cells. Similarly, TPR-MET was found to be tyrosine phosphorylated itself in Met immunoprecipitations and coprecipitated with a prominent Mr 140,000–145,000 band. There were additional prominently tyrosine phosphorylated proteins with apparent molecular masses of Mr 50,000–60,000 and larger than Mr 300,000 found in a complex with TPR-MET (Fig. 3A
, left). Comparing TPR-MET and BCR-ABL immunoprecipitations also indicated that both oncogenes formed different signaling complex with tyrosine phosphorylated proteins in BaF3 cells. Treatment of BaF3.TPR-MET cells with SU11274 reduced tyrosine phosphorylation within 2 h but was not maximal until 18 h of treatment (Fig. 3B)
. In addition, the Abl kinase inhibitor STI-571 did not alter tyrosine phosphorylation of cellular proteins in BaF3.TPR-MET cells (Fig. 3C)
. These data suggest that SU11274 specifically inhibits TPR-MET-induced tyrosine phosphorylation relative to BCR-ABL.
|
, top). To determine whether SU11274 also inhibits the activation of the c-Met receptor, we used HGF-stimulated and -unstimulated H69 cells. After ligand activation, the Met receptor becomes inducibly phosphorylated at multiple sites, including the major autophosphorylation sites Tyr1230/1234/1235 (homologous to Tyr361/365/366 in TPR-MET). Phosphorylation at these sites correlates with activation of the Met kinase. Using phospho-specific antibodies to Tyr1230/1234/1235, we found that SU11274 completely blocked the increase in phosphorylation (Fig. 4A
, bottom). In addition, there was no detectable tyrosine phosphorylation of Met in anti-Met immunoprecipitations of HGF-stimulated H69 cells after SU11274 treatment (data not shown). This is consistent with the above data demonstrating an inhibition of HGF-induced proliferation in H69 cells at micromolar concentrations.
|
). This would suggest that inhibition of Met kinase activity leads to reduced activation of the PI3K pathway in these cells.
Inhibition of Met Kinase Activity by SU11274 Induces Apoptosis and Cell Cycle Arrest in TPR-MET-transformed BaF3 Cells.
Apoptosis is a complex cellular function that is regulated in part through the PI3K pathway. Down-regulation of PI3K activity through inhibition of Met tyrosine kinase activity in TPR-MET-transformed cells is, therefore, expected to induce an increase in apoptosis. We measured the change in Annexin V-positive staining of cells, an indication for increased exposure of phosphatidylserine to the outer cell membrane during apoptosis. Using TPR-MET-transformed BaF3 cells, we found that treatment with SU11274 (18 h, 1 µM) led to an increase in Annexin V-positive cells compared with DMSO-treated cells (Fig. 5A
, top left). In the control cells, 5% of the total population showed signs of apoptosis, however, the number of apoptotic cells increased to 24% after SU11274 treatment. On average, 9.0 ± 2.5% of the cells were in early apoptosis (Annexin V positive), and 14.8 ± 4.9% of the cells were in late apoptosis (Annexin V plus propidium iodide positive). We next measured the activation status of caspase-3, a downstream effector of the proapoptotic caspase-9. Similar to the previous data, we observed a consistent increase in caspase-3 activity (2.5 ± 0.6-fold increase; n = 3; P < 0.01) compared with DMSO-treated cells (Fig. 5B)
.
|
. The percentage of cells in G1 phase increased from 42.4% to 70.6% in SU11274 (5 µM)-treated cells, whereas the percentage of cells in S phase (reduced from 45.4% to 21.1%) and G2-M phase (reduced from 12.2% to 8.3%) decreased. This suggests that inhibition of TPR-MET kinase activity leads to G1 cell cycle arrest in the transformed cells. In addition, there was an increase of cells in sub-G1 phase, which was consistent with apoptotic cells. These data demonstrate that SU11274 induces cell cycle arrest as well as apoptosis, and both events in combination are likely to contribute to the reduced cell growth of SU11274-treated TPR-MET-transformed cells. |
DISCUSSION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
The Met pathway itself shares homology with semaphorins and semaphorin receptors (plexins), which are also involved in cell scattering (23 , 24) . There is also evidence that semaphorins may use Met for regulation of cell scattering (25) . Here, we show that TPR-MET can lead to enhanced migration of BaF3 cells, and this can be readily inhibited with SU11274. This is likely mediated through downstream inhibition of the PI3K pathway and cytoskeletal proteins. Because HGF/Met signaling has been implicated in processes involving cellular motility and invasive growth, it has been closely associated with integrins. In the MDA-MB-231 carcinoma cell line, HGF/Met signaling sustained cell adhesion on laminin-1, laminin-5, fibronectin, and vitronectin via a PI3K-dependent mechanism (26) . This was followed by increased invasiveness through reconstituted basement membranes. HGF stimulation of Met has also been shown to induce phosphorylation of cytoskeletal proteins paxillin, p125FAK, and Pyk2, and potential activation of cdc42 and Rac, thus forming filopodia and lamellopodia (26) . With the increased migration of cells, activated Met can then ultimately lead to enhanced metastasis.
It is, therefore, proposed that inhibition of Met function would block tumor invasion, angiogenesis, growth, and proliferation and multiple other biological effects associated with Met activation. As pointed out before, small molecule inhibitors specific against c-Met have not yet been reported. However, in addition to targeting the c-Met tyrosine kinase, there are several additional pathways that are currently being explored. Bardelli et al. (27)
have reported using peptides against tyrosines of c-Met located in the kinase activation loop with N-terminal sequence from the Antennapedia protein for internalization, as well as located in the COOH-tail of c-Met. Peptides derived from the c-Met receptor tail, and not from the kinase domain, bind the receptor, inhibit kinase activity, and inhibit HGF-mediated invasive growth on A549 cells by approximately 50% (invasion, cell migration, and branched morphogenesis). HGF also leads to plasmin activation. Webb et al. (28)
have reported that geldanamycins, anisamycin antibiotics, lead to decreased plasmin activation at femtomolar concentrations. Geldanamycins, at nanomolar concentrations, have been shown to result in down-regulation of c-Met, inhibition of HGF-mediated cell motility and invasion in MDCK-2 cells, and phenotypic reversion of Met-transformed NIH3T3 cells. We have recently shown that geldanamycins can modulate the c-Met pathway in small cell lung cancer (29)
. However, geldanamycins may not be specific only for c-Met. Another inhibitor of the HGF/Met pathway is NK2, a naturally occurring alternatively spliced form of HGF. NK2 possesses the N-domain and the first two kringle domains and can act as either an antagonist or partial agonist, depending on the target cells and culture conditions. NK2 has been reported to inhibit growth but facilitates metastasis of transplanted Met-containing melanoma cells in NK2-HGF bitransgenic mice (30)
. In addition, another antagonist of HGF, NK4, was reported to be generated by proteolytic digestion of HGF (31)
. NK4 is a truncated HGF composed of the NH2-terminal hairpin domain and four kringle domains in the 
chain of HGF. It retains c-Met receptor binding properties without mediating biological responses. NK4 antagonizes HGF-induced tyrosine phosphorylation of c-Met, resulting in inhibition of HGF-induced motility and invasion of HT115 human colorectal cancer cells, as well as angiogenesis (32)
. Also, when administered to pancreatic tumor-bearing mice, NK4 inhibited growth, invasion, and disseminating metastasis of pancreatic cancer cells and prolonged the life span of these mice (33)
. Also, a soluble chimeric form of c-Met was shown to retain full capacity to bind HGF and, therefore, neutralize HGF activity (34)
. NK4, pro-HGF (uncleavable HGF), and the decoy c-Met receptor have been shown to inhibit mutant c-Met-induced transformation of NIH3T3 cells (35)
. Attempts at inhibiting c-Met signaling through ribozyme-mediated down-regulation have been reported in breast cancer and glioblastoma with interesting and positive results (36
, 37)
. Examples include decreased tumorigenic growth and reduced induction of HGF-dependent gene expression in glioblastoma cells (36)
. Interestingly, the reduction in c-Met protein levels leads to a decrease in the activation of survival pathway and, therefore, to increased apoptosis (38
, 39) . It still remains unknown as to how much c-Met inhibition is required to achieve clinically beneficial antitumor and antimetastatic results. The answer may potentially be different depending on whether the "tumorigenic culprit" lies with c-Met expression or mutations of the receptor tyrosine kinase. Another intriguing area of research, when specific c-Met inhibitors are available, would be to test the drug efficacies against different mutant forms of the Met oncoprotein. It is plausible that some mutations of c-Met may cause resistance, or conversely a greater susceptibility, to the inhibitors. This certainly translates into important clinical decisions regarding therapeutic choices. Obviously, much more work needs to be done in dissecting the potential correlation between c-Met mutations and its specific inhibitors to arrive at better designed anticancer therapies. Efforts in resolving the crystal structure of the c-Met receptor tyrosine kinase would likely be helpful to allow a starting point in rational design of specific c-Met kinase inhibitors in the future.
As done in CML (with activated Abl in BCR-ABL; Ref. 40 ), gastrointestinal stromal tumor (with activated c-Kit; Ref. 41 ) and non-small cell lung cancer (with EGFR overexpression; Ref. 42 ), small molecule inhibitors are rationally designed to the ATP pocket of the tyrosine kinase. Our model of TPR-MET has considerable homologies with the BCR-ABL model. Similar to BCR-ABL, TPR-MET constitutively activates signaling pathways that are thought to be crucial for transformation, such as pathways regulating the function of Ras (43 , 44) or PI3K (45) . In addition, at least in our cell line model system, TPR-MET, like BCR-ABL, seems to be sufficient for transformation and does not require an apparent second mutation. Thus, designing inhibitors against the tyrosine kinase domain of Met would be very useful, similar to Gleevec in CML with BCR-ABL.
In studying signal transduction pathways downstream of activated Met, we have recently shown that PI3K is an important pathway. PI3K is responsible for cellular regulation, including events such as proliferation, reduced apoptosis, anchorage independence, and intracellular vesicle trafficking/secretion (46 , 47) . Phosphorylation of AKT (48 , 49) and FKHR (50 , 51) , downstream of PI3K, leads to cell survival, whereas herein we show SU11274 treatment of TPR-MET cells leads to decreased phosphorylation of FKHR and AKT, thereby leading to apoptosis. HGF/Met activation has been shown to protect against cell death in human glioblastoma cells treated with cytotoxic agents. Treating cells with inhibitors of PI3K, such as wortmannin and LY249002, can block this promotion of cell survival by HGF (39) . It would now be useful to determine whether there is any synergism between SU11274 and PI3K inhibition.
In summary, these studies have characterized the dramatic effects of a prototype Met inhibitor, SU11274, on Met tyrosine kinase activity and function in a novel model system. Collectively, these results illustrate the potential of targeting Met in cancers associated with activated forms of the Met receptor tyrosine kinase. In the future, it would be useful to extend these results to evaluate Met inhibitors in mouse tumor models in support of potential clinical studies.
|
FOOTNOTES |
|---|
1 Supported by an American Cancer Society Research Scholar grant (to M. S. and R. S.) and an American Society of Clinical Oncology Young Investigator Award (to P. M.). 
2 To whom requests for reprints should be addressed, at Department of Medicine, University of Chicago, Pritzker School of Medicine, 5841 S. Maryland Avenue, MC 2115, M255A, Chicago, IL 60637-1470. Phone: (773) 702-4399; Fax: 773-834-1798; E-mail: rsalgia{at}medicine.bsd.uchicago.edu
3 The abbreviations used are: TPR, translocated promoter region; HGF, hepatocyte growth factor; CML, chronic myelogenous leukemia; EGFR, epidermal growth factor receptor; PDGF, platelet-derived growth factor; FGFR, fibroblast growth factor receptor; JAK, Janus-activated kinase; PI3K, phosphatidylinositol-3'-kinase.
Received 3/19/03. Revised 6/ 9/03. Accepted 6/17/03.
|
REFERENCES |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
. Curr. Biol., 7: 261-269, 1997.[Medline]
This article has been cited by other articles:
|
|
 |
|
  A. E. Moore, A. Greenhough, H. R. Roberts, D. J. Hicks, H. A. Patsos, A. C. Williams, and C. Paraskeva HGF/Met signalling promotes PGE2 biogenesis via regulation of COX-2 and 15-PGDH expression in colorectal cancer cells Carcinogenesis, October 1, 2009; 30(10): 1796 - 1804. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Coxon, K. Rex, S. Meyer, J. Sun, J. Sun, Q. Chen, R. Radinsky, R. Kendall, and T. L. Burgess Soluble c-Met receptors inhibit phosphorylation of c-Met and growth of hepatocyte growth factor: c-Met-dependent tumors in animal models Mol. Cancer Ther., May 1, 2009; 8(5): 1119 - 1125. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Y. Seiwert, R. Jagadeeswaran, L. Faoro, V. Janamanchi, V. Nallasura, M. El Dinali, S. Yala, R. Kanteti, E. E.W. Cohen, M. W. Lingen, et al. The MET Receptor Tyrosine Kinase Is a Potential Novel Therapeutic Target for Head and Neck Squamous Cell Carcinoma Cancer Res., April 1, 2009; 69(7): 3021 - 3031. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Leroy, C. Fialin, A. Sirvent, V. Simon, S. Urbach, J. Poncet, B. Robert, P. Jouin, and S. Roche Quantitative Phosphoproteomics Reveals a Cluster of Tyrosine Kinases That Mediates Src Invasive Activity in Advanced Colon Carcinoma Cells Cancer Res., March 15, 2009; 69(6): 2279 - 2286. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. K.Y. Chan, B. A. Lutterbach, B.-S. Pan, I. Kariv, and A. A. Szewczak High-Throughput Analysis of HGF-Stimulated Cell Scattering J Biomol Screen, October 1, 2008; 13(9): 847 - 854. [Abstract] [PDF]
|
|
|
|
|
|
Y. Zhang, P. J. Kaplan-Lefko, K. Rex, Y. Yang, J. Moriguchi, T. Osgood, B. Mattson, A. Coxon, M. Reese, T.-S. Kim, et al. Identification of a Novel Recepteur d'Origine Nantais/c-Met Small-Molecule Kinase Inhibitor with Antitumor Activity In vivo Cancer Res., August 15, 2008; 68(16): 6680 - 6687. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Basilico, A. Arnesano, M. Galluzzo, P. M. Comoglio, and P. Michieli A High Affinity Hepatocyte Growth Factor-binding Site in the Immunoglobulin-like Region of Met J. Biol. Chem., July 25, 2008; 283(30): 21267 - 21277. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Ganapathipillai, M. Medova, D. M. Aebersold, P. W. Manley, S. Berthou, B. Streit, W. Blank-Liss, R. H. Greiner, B. Rothen-Rutishauser, and Y. Zimmer Coupling of Mutated Met Variants to DNA Repair via Abl and Rad51 Cancer Res., July 15, 2008; 68(14): 5769 - 5777. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Peruzzi and D. P Bottaro Targeting the c-Met Signaling Pathway in Cancer Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 61 - 68. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Shattuck, J. K. Miller, K. L. Carraway III, and C. Sweeney Met Receptor Contributes to Trastuzumab Resistance of Her2-Overexpressing Breast Cancer Cells Cancer Res., March 1, 2008; 68(5): 1471 - 1477. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. F. Bellon, P. Kaplan-Lefko, Y. Yang, Y. Zhang, J. Moriguchi, K. Rex, C. W. Johnson, P. E. Rose, A. M. Long, A. B. O'Connor, et al. c-Met Inhibitors with Novel Binding Mode Show Activity against Several Hereditary Papillary Renal Cell Carcinoma-related Mutations J. Biol. Chem., February 1, 2008; 283(5): 2675 - 2683. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Salgia c-Met Receptor Tyrosine Kinase as a Therapeutic Target in Cancer ASCO Educational Book, January 1, 2008; 2008(1): 113 - 118. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. V. Sharma and J. Settleman Oncogene addiction: setting the stage for molecularly targeted cancer therapy Genes & Dev., December 15, 2007; 21(24): 3214 - 3231. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Beroukhim, G. Getz, L. Nghiemphu, J. Barretina, T. Hsueh, D. Linhart, I. Vivanco, J. C. Lee, J. H. Huang, S. Alexander, et al. Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma PNAS, December 11, 2007; 104(50): 20007 - 20012. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. H. Huang, A. Mukasa, R. Bonavia, R. A. Flynn, Z. E. Brewer, W. K. Cavenee, F. B. Furnari, and F. M. White Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma PNAS, July 31, 2007; 104(31): 12867 - 12872. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Jagadeeswaran, S. Jagadeeswaran, V. P. Bindokas, and R. Salgia Activation of HGF/c-Met pathway contributes to the reactive oxygen species generation and motility of small cell lung cancer cells Am J Physiol Lung Cell Mol Physiol, June 1, 2007; 292(6): L1488 - L1494. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Puri, A. Khramtsov, S. Ahmed, V. Nallasura, J. T. Hetzel, R. Jagadeeswaran, G. Karczmar, and R. Salgia A Selective Small Molecule Inhibitor of c-Met, PHA665752, Inhibits Tumorigenicity and Angiogenesis in Mouse Lung Cancer Xenografts Cancer Res., April 15, 2007; 67(8): 3529 - 3534. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Puri, S. Ahmed, V. Janamanchi, M. Tretiakova, O. Zumba, T. Krausz, R. Jagadeeswaran, and R. Salgia c-Met Is a Potentially New Therapeutic Target for Treatment of Human Melanoma Clin. Cancer Res., April 1, 2007; 13(7): 2246 - 2253. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Yu, P. M. Weinberger, C. Sasaki, B. L. Egleston, W. F. Speier IV, B. Haffty, D. Kowalski, R. Camp, D. Rimm, E. Vairaktaris, et al. Phosphorylation of Akt (Ser473) Predicts Poor Clinical Outcome in Oropharyngeal Squamous Cell Cancer Cancer Epidemiol. Biomarkers Prev., March 1, 2007; 16(3): 553 - 558. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. M. Linehan, P. A. Pinto, R. Srinivasan, M. Merino, P. Choyke, L. Choyke, J. Coleman, J. Toro, G. Glenn, C. Vocke, et al. Identification of the Genes for Kidney Cancer: Opportunity for Disease-Specific Targeted Therapeutics Clin. Cancer Res., January 15, 2007; 13(2): 671s - 679s. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Iliopoulos Molecular Biology of Renal Cell Cancer and the Identification of Therapeutic Targets J. Clin. Oncol., December 10, 2006; 24(35): 5593 - 5600. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Mukhopadhyay, E. A. Sausville, J. H. Doroshow, and K. K. Roy Molecular Mechanism of Adaphostin-mediated G1 Arrest in Prostate Cancer (PC-3) Cells: SIGNALING EVENTS MEDIATED BY HEPATOCYTE GROWTH FACTOR RECEPTOR, c-Met, AND p38 MAPK PATHWAYS J. Biol. Chem., December 8, 2006; 281(49): 37330 - 37344. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Anderson, R. Harrison, P. A. Atherfold, M. J. Campbell, S. J. Darnton, J. Obszynska, and J. A.Z Jankowski Met receptor signaling: a key effector in esophageal adenocarcinoma. Clin. Cancer Res., October 15, 2006; 12(20): 5936 - 5943. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Cassinelli, C. Lanzi, G. Petrangolini, M. Tortoreto, G. Pratesi, G. Cuccuru, D. Laccabue, R. Supino, S. Belluco, E. Favini, et al. Inhibition of c-Met and prevention of spontaneous metastatic spreading by the 2-indolinone RPI-1. Mol. Cancer Ther., September 1, 2006; 5(9): 2388 - 2397. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Mazzone and P. M. Comoglio The Met pathway: master switch and drug target in cancer progression FASEB J, August 1, 2006; 20(10): 1611 - 1621. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Walz, B. J. Crowley, H. E. Hudon, J. L. Gramlich, D. S. Neuberg, K. Podar, J. D. Griffin, and M. Sattler Activated Jak2 with the V617F Point Mutation Promotes G1/S Phase Transition J. Biol. Chem., June 30, 2006; 281(26): 18177 - 18183. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Peruzzi and D. P. Bottaro Targeting the c-Met Signaling Pathway in Cancer. Clin. Cancer Res., June 15, 2006; 12(12): 3657 - 3660. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Jagadeeswaran, P. C. Ma, T. Y. Seiwert, S. Jagadeeswaran, O. Zumba, V. Nallasura, S. Ahmed, R. Filiberti, M. Paganuzzi, R. Puntoni, et al. Functional Analysis of c-Met/Hepatocyte Growth Factor Pathway in Malignant Pleural Mesothelioma Cancer Res., January 1, 2006; 66(1): 352 - 361. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Shibata, S. Uryu, A. Kokubu, F. Hosoda, M. Ohki, T. Sakiyama, Y. Matsuno, R. Tsuchiya, Y. Kanai, T. Kondo, et al. Genetic Classification of Lung Adenocarcinoma Based on Array-Based Comparative Genomic Hybridization Analysis: Its Association with Clinicopathologic Features Clin. Cancer Res., September 1, 2005; 11(17): 6177 - 6185. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. C. Ma, E. Schaefer, J. G. Christensen, and R. Salgia A Selective Small Molecule c-MET Inhibitor, PHA665752, Cooperates with Rapamycin Clin. Cancer Res., March 15, 2005; 11(6): 2312 - 2319. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. C. Ma, R. Jagadeeswaran, S. Jagadeesh, M. S. Tretiakova, V. Nallasura, E. A. Fox, M. Hansen, E. Schaefer, K. Naoki, A. Lader, et al. Functional Expression and Mutations of c-Met and Its Therapeutic Inhibition with SU11274 and Small Interfering RNA in Non-Small Cell Lung Cancer Cancer Res., February 15, 2005; 65(4): 1479 - 1488. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Richard, R. Lidereau, S. Giraud, and on behalf of the French inherited kidney tumours c The growing family of hereditary renal cell carcinoma Nephrol. Dial. Transplant., December 1, 2004; 19(12): 2954 - 2958. [Full Text] [PDF]
|
|
|
|
|
|
P. C. Ma, T. Kijima, G. Maulik, E. A. Fox, M. Sattler, J. D. Griffin, B. E. Johnson, and R. Salgia c-MET Mutational Analysis in Small Cell Lung Cancer: Novel Juxtamembrane Domain Mutations Regulating Cytoskeletal Functions Cancer Res., October 1, 2003; 63(19): 6272 - 6281. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
) or TPR-MET in the presence (
) or absence (
) of interleukin 3 in response to different concentrations of SU11274 was determined after 18 h (n = 3). B, BaF3 cells transformed by tyrosine kinase oncogenes were treated for 18 h with SU11274 (1 µM; n = 3). C, TPR-MET-transformed BaF3 cells were either left untreated (
) cells in the presence of HGF (40 ng/ml) in response to different concentrations of SU11274 was determined after 72 h and shown in a typical experiment (n = 3).
